Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer - Trial NCT06349967
Access comprehensive clinical trial information for NCT06349967 through Pure Global AI's free database. This Phase 2 trial is sponsored by West China Hospital and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 59 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
West China Hospital
Timeline & Enrollment
Phase 2
Apr 30, 2024
May 30, 2027
Primary Outcome
overall response rate (ORR)
Summary
Currently, standard treatment options for gastric cancer failed to first-line treatment
 include monotherapy with paclitaxel/irinotecan/docetaxel/albumin paclitaxel, or paclitaxel
 combined with ramucirumab. However, the efficacy of these regimens is still far from
 satisfactory. The aim of the study is to evaluate the efficacy and safety of nab-paclitaxel
 combined with cadonilimab for the second-line treatment of advanced gastric cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06349967
Non-Device Trial